Welcome to our dedicated page for Proto Labs SEC filings (Ticker: PRLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Proto Labs, Inc. (Protolabs) (NYSE: PRLB) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Minnesota corporation with common stock listed on the New York Stock Exchange, Protolabs submits periodic and current reports that document its financial condition, operating results, and significant corporate events.
Investors researching PRLB can use this page to review annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, revenue by service line (Injection Molding, CNC Machining, 3D Printing, Sheet Metal, and Other Revenue), and discussions of non-GAAP measures such as adjusted EBITDA, non-GAAP gross margin, and non-GAAP net income. These filings explain how management evaluates performance and how digital factory and Protolabs Network fulfillment contribute to overall results.
The page also aggregates current reports on Form 8-K, which Protolabs uses to announce material events. Recent 8-K filings reference quarterly earnings press releases and leadership changes, including the appointment of a Chief Technology and AI Officer and related executive transitions. Such filings may also incorporate press releases as exhibits, giving readers direct access to management commentary and outlook statements.
Alongside these core reports, users can monitor exhibits related to executive compensation, inducement equity awards under NYSE Rule 303A.08, and severance arrangements referenced in executive agreements. Insider transaction reports on Form 4, proxy statements on Schedule 14A, and other ownership or governance-related filings, when available, help investors understand how executives and directors are compensated and how they hold or transact in PRLB shares.
Stock Titan enhances this information with AI-powered summaries that highlight key points in lengthy documents, such as revenue trends, margin drivers, and notable risk factors. Real-time updates from EDGAR ensure that new Protolabs filings, including 10-K, 10-Q, 8-K, and Form 4 reports, are quickly reflected, allowing users to review the underlying disclosures while relying on AI-generated explanations to interpret complex accounting and regulatory language.
Proto Labs (symbol PRLB) received a Rule 144 notice from shareholder Oleg Ryaboy covering planned sales of common stock. The notice states an intention to sell 7,178 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $393,329.99, at a time when 23,678,745 common shares were outstanding.
The shares to be sold come from option exercises under a registered plan on 01/15/2026, where 3,048 and 4,130 common shares were acquired for cash on that same date. The filing also lists prior sales by the same shareholder over the past three months: 695, 9,710, 7,026, and 6,669 common shares, with gross proceeds of $34,686.76, $471,629.27, $384,413.54, and $357,327.02, respectively.
Form 144 discloses that Oleg Ryaboy plans to sell 7,026 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/08/2026, with an indicated aggregate market value of 384,413.54. The stock is listed on the NYSE, and the issuer has 23,678,745 shares of this class outstanding.
The shares to be sold were acquired on 01/08/2026 by exercising options under a registered plan, in two transactions of 1,164 and 5,862 shares paid in cash. The notice also reports that during the past three months, Oleg Ryaboy sold additional common shares in three transactions, including 9,710 shares for gross proceeds of 471,629.27 on 11/07/2025 and 6,669 shares for 357,327.02 on 01/07/2026. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
PRLB has a shareholder filing a notice to sell common stock under Rule 144. The filing covers a proposed sale of 6,669 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $357,327.02. The shares were acquired on 01/07/2026 by exercising options under a registered plan and were paid for in cash the same day.
The notice also lists recent sales in the past three months for the same seller, including 9,710 common shares sold on 11/07/2025 for gross proceeds of $471,629.27 and 695 common shares sold on 11/25/2025 for $34,686.76. By signing, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s operations.
Proto Labs Inc. Chief Operations Officer reported an amended insider transaction involving company common stock. On November 25, 2025, the officer exercised 3,048 employee stock options at an exercise price of $33.84 per share, receiving the same number of common shares. That same day, the officer sold 3,048 common shares at a weighted average price of $50.1741 per share under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025. After these transactions, the officer beneficially owned 28,898 common shares directly. The filing also clarifies that the stock options were fully vested and corrects the stated expiration date of the options to February 14, 2026, fixing a clerical error in a prior report while leaving all other transaction details unchanged.
Proto Labs, Inc. (PRLB) reported an insider transaction by its Chief Operations Officer on a Form 4. On 11/25/2025, the officer exercised an employee stock option for 3,048 shares of common stock at an exercise price of $33.84 per share, then sold 3,048 shares of common stock in open-market transactions at a weighted average price of $50.1741 per share. After these transactions, the officer directly beneficially owned 28,898 shares of Proto Labs common stock and held 4,664 employee stock options following the reported exercise. The filing notes that the trades were made under a Rule 10b5-1 trading plan adopted on August 15, 2025, and that the ownership total includes 57 shares acquired through the company’s employee stock purchase plan.
Proto Labs (PRLB) insider Oleg Ryaboy filed a Form 144 notice covering the potential sale of 695 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $34,686.76 and an approximate sale date of 11/25/2025.
The 695 shares were acquired on 05/14/2024 through an Employee Stock Purchase Plan and paid for in cash. The filing also reports that during the past three months, Ryaboy sold 9,710 common shares on 11/07/2025 for gross proceeds of $471,629.27. By signing the notice, he represents that he is not aware of any undisclosed material adverse information about Proto Labs.
Proto Labs (PRLB) has a Form 144 notice for a proposed sale of 3,048 shares of its common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $150,144.48. The filing notes that 23,678,745 shares of common stock were outstanding when the notice was prepared.
The seller acquired the 3,048 shares on 11/25/2025 by exercising stock options granted by the issuer and paid the purchase price in cash on the same date. The Form 144 also includes the standard representation that the seller does not know of any undisclosed material adverse information about Proto Labs’ current or prospective operations.
Proto Labs, Inc. (PRLB) reported an insider equity award for its Chief Technology & AI Officer on a Form 4. On 11/17/2025, the officer received 3,718 shares of common stock as a restricted stock unit grant at a price of $0, increasing direct beneficial ownership to 3,718 shares. The filing also reports a grant of an employee stock option for 6,818 shares of common stock with a $47.07 exercise price, expiring on 11/17/2035.
The restricted stock units vest annually over four years starting on November 15, 2026, and the stock option vests on the same schedule. This structure is designed so that the officer earns the awards gradually over time, which can help align long-term incentives with company performance and retention.
Disciplined Growth Investors, Inc. filed Amendment No. 6 to a Schedule 13G reporting beneficial ownership of 2,592,373 Proto Labs (PRLB) common shares, representing 10.9% of the class as of 09/30/2025.
The filer reports sole voting power over 2,316,889 shares and sole dispositive power over 2,592,373 shares, with no shared voting or dispositive power. The reporting person is classified as an investment adviser (IA).
In its certification, the filer states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Proto Labs.
PRLB filed a Form 144 for a proposed sale of 9,710 common shares, with an aggregate market value of $471,629.27. The shares may be sold through Morgan Stanley Smith Barney LLC, with an approximate sale date of 11/07/2025 on the NYSE. The securities were acquired primarily via restricted stock vesting under a registered plan and an employee stock purchase plan, including tranches such as 1,567 shares vested on 02/13/2024 and 797 shares purchased on 11/15/2023.